 |
|
|
|
| Featured Article: Improving Members' Outcomes Across the Continuum of Diabetes |
|
Improving Members' Outcomes Across the Continuum of Diabetes: Assessing the Impact of New Measures, Technologies, and Benefit Design Strategies, is an educational activity for managed care health professionals, especially pharmacy directors and medical directors, with an interest in improving members' outcomes in diabetes through the use of new technologies and innovative benefit design strategies.
Diabetes has reached epidemic proportions in the United States, where there are approximately 20.8 million diabetics. The total cost of diabetes in 2002 was about $132.6 billion, including $91.8 billion in direct and $40.8 billion in indirect costs. Diabetic managed care members consume more healthcare resources and cost approximately 2.4 times more than members without diabetes.
This dynamic activity provides participants with an update on diabetes in the United States, discusses new and investigational pharmacotherapeutic agents and technologies in diabetes treatment, and evaluates and debates new benefit design strategies and their potential application to this disease state.
The Chair of this activity is Lawrence Blonde, MD, FACP, FACE. Dr. Blonde is Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Ochsner Clinic Foundation in New Orleans, where he is also Director of the Associate Internal Medicine Residency Program. This activity also features Andrew J. Ahmann, MD, MS; Jan Berger, MD, MJ; and Curtis L. Triplitt, PharmD, CDE. After completing this activity participants should be able to do the following:
- Describe current gaps in the management of diabetes in the US healthcare system, given current prevalence and epidemiologic data.
- Define current standards of care for the management of diabetes, based on consensus recommendations from professional associations and societies.
- Identify members who can be appropriately treated with new and emerging diabetes technologies and classes of medications.
- Analyze the potential impact of novel pharmacy benefit designs in the area of diabetes management, given experiential data from a large employer.
To learn more about this and other excellent online CE programs for pharmacists and allied health professionals, please visit www.RxSchool.com.
 The Bimark Center for Medical Education (BCME) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (No. 799).
This activity is approved for 1.0 hour (0.10 CEU) of continuing education credit in states that recognize ACPE-accredited providers. The ACPE Universal Program number for this activity is 799-000-07-003-H01.
To receive CE credit for this course, please visit: www.rxschool.com, or send an e-mail to info@rxschool.com.
|
As a registered user of our website, you have opted-in to receive this newsletter. To change your subscription information or to unsubscribe, please login to your account for newsletter and
email options under "Edit Profile".
2601 Blake St Suite 400 | Denver, Colorado 80205
888-862-4415
© 2006 Pharmacy Choice (PC) - All rights reserved.
Disclaimer:
The information contained in this newsletter is intended as an educational aid only. All Treatments or procedures are intended to serve
as an information resource for pharmacists, physicians or other competent healthcare professionals performing the consultation or
evaluation of patients and must be interpreted in view of all attendant circumstances, indications and contraindications. The use of any
of these products or information is at your sole risk. These products are provided "as is" and "as available" for use, without warranties
of any kind, either express or implied. PC makes no representation or warranty as to the accuracy, reliability, timeliness,
usefulness or completeness of any of the information contained in the products. Additionally, PC makes no representation or
warranties as to the opinions or other service or data you may access, download or use as a result of use of the PC products.
All implied warranties of merchantability and fitness for a particular purpose or use are hereby excluded. PC does not assume
any responsibility or risk for your use of the PC products or information.
|
|
|